MD Anderson Cancer Center Research Demonstrates Clinical Applicability of ANGLE plc’s ‘Blood Biopsy’ Technology

Poster presentation at AACC August 2 shows harvest of breast cancer cells in blood using Parsortix™ cell separation system enables subsequent gene expression analysis

ANGLE plc (AIM:AGL OTCQX:ANPCY), the UK-based medical diagnostics company with pioneering products for cancer diagnostics and fetal health, announces a poster presentation by researchers from the University of Texas MD Anderson Cancer Center describing clinically-relevant results from a study using its lead product, the Parsortix cell separation system, to harvest breast cancer cells in blood for subsequent molecular characterization. The poster will be presented at the American Association for Clinical Chemistry Annual Meeting July 31 - August 4.

The research team, led by Dr. James M. Reuben, Professor, Department of Hematopathology, MD Anderson Cancer Center, confirmed the ability to perform advanced molecular analysis on breast cancer cells isolated from blood samples using the Parsortix liquid biopsy technology. The researchers note the ability of the Parsortix method to harvest circulating tumor cells (CTCs) without the use of antibodies.

In the study, entitled "Antibody-free microfluidics-based circulating tumor cell enrichment by ANGLE plc Parsortix and downstream molecular characterization by Affymetrix branched DNA technology“, the researchers describe the advantages of being able to perform gene expression analysis on the harvested cells.

Following capture of breast cancer cells that were spiked into healthy donor blood samples, the researchers measured the expression of several genes, including specific breast-cancer related genes. The study results show high specificity for detection of the targeted genes and strong sensitivity for highly expressed genes in dilutions of the harvested cell extracts. The ability to measure gene expression in CTCs has the potential to provide more clinically actionable information than simple detection or quantification of tumor cells in blood.

This new research demonstrates the potential to obtain particularly detailed information from CTCs regarding the cells being analysed. Liquid biopsy using the Parsortix system, combined with molecular characterization of the CTCs, can be repeated over time without requiring surgical removal of a tumor sample. It offers a less invasive and more personalized approach to monitoring for response to therapy and disease progression.

“Multiplexed gene expression analysis will be a very important approach in enabling new clinical diagnostic capability in oncology through liquid biopsy. But this is technically demanding, and the most leading edge techniques will need to be applied with CTCs if liquid biopsy is to be robust and versatile. CTC analysis using array based methods is an area of particular interest to us, and this research is an important step in proving their efficacy with our cell separation system, and in developing the required methodology. Coming as they do from the renowned MD Anderson Cancer Center, these developments and conclusions are encouraging and exciting,” said ANGLE Chief Technology Officer, Shane Booth.

About ANGLE plc

ANGLE is a UK-based specialist medtech company commercializing the Parsortix system, a cell separation technology that enables a simple blood test to capture targeted cells for investigation, such as circulating tumor cells (CTCs) for molecular profiling and analysis. Parsortix can help deliver targeted cancer diagnostics that has the potential to inform personalized treatment of cancer. It is also designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. ANGLE has established formal collaborations with world-class cancer centers and is working with these cancer centers to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy. In addition to cancer cells, the Parsortix technology has the potential for deployment for other clinically significant cell types in the future.

ANGLE is a public company trading on the AIM market of the London Stock Exchange under the ticker symbol AGL and on the OTCQX market in the US under the ticker symbol ANPCY. For more information, www.angleplc.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005221/en/

ANGLE plcPeggy Robinson, 914-525-5928Vice PresidentorMedia ContactBrandwidth Solutions LLCDebra Harrsch, [e-mail]